John Gribben, MD, DSc, FRCPath, FMed Sci, is a Consultant Hematologist and Medical Oncologist, at Barts Cancer Institute, Queen Mary University of London.
His postgraduate studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. He continued his training at the Dana-Farber Cancer Institute, Harvard Medical School. In 1992, he was appointed to the Faculty at Harvard Medical School, where he remained as an Associate Professor of Medicine and Attending Physician at the Dana-Farber Cancer Institute, and Brigham and Women’s Hospital, until returning to London in 2005. He is a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.
Prof. Gribben’s primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell tumor antigens, and the detection and treatment of measurable residual disease (MRD) in leukemia and lymphoma.